Cantex's once daily, orally administered,
azeliragon inhibits interactions of the receptor for advanced
glycation end products (RAGE)
Researchers showed RAGE inhibition to be a
potential target for treatment of triple-negative breast cancer
suppressing tumor progression and metastasis
WESTON,
Fla., Aug. 10, 2023 /PRNewswire/ -- Cantex
Pharmaceuticals, Inc., a clinical-stage pharmaceutical company
focused on developing transformative therapies for cancer and
other life-threatening medical conditions for which new treatments
are urgently needed, today announced the publication in the
peer-reviewed journal, npj Breast Cancer, a Nature Portfolio
journal published in partnership with Breast Cancer Research
Foundation, with results from in vitro and in vivo
models for triple-negative breast cancer showing suppression of
metastasis and tumor progression by RAGE inhibition. Cantex's
azeliragon, currently in phase 2/3 development for the treatment of
major cancers, complications of cancer treatment, and the treatment
of other life-threatening illnesses, is a RAGE inhibitor that is
orally administered and taken once daily.
In the paper titled, "RAGE inhibitor TTP488 (Azeliragon)
suppresses metastasis in triple-negative breast cancer,"
researchers investigated whether azeliragon impairs
triple-negative breast cancer progression and metastasis and the
mechanisms by which RAGE inhibition by azeliragon mediates breast
cancer progression and metastasis. The authors showed that
azeliragon exerts a potent anti-metastatic effect in orthotopic
xenograft and experimental metastasis models of triple-negative
breast cancer, which they corroborated by demonstrating that RAGE
inhibition impairs biological mechanisms that drive cancer
metastasis.
"This is a major publication supporting the role of RAGE
inhibition in progressive and deadly cancers like triple-negative
breast cancer," said Stephen G.
Marcus, M.D., Cantex's Chief Executive Officer. "We
congratulate the authors on their critically important work and
look forward to collaborating with them as we seek to unlock the
potential of azeliragon and RAGE inhibition to treat
triple-negative breast cancer and other major cancers, for which
improved treatment is greatly needed."
"Our results show that azeliragon impairs metastasis of
triple-negative breast cancer, clarifying signaling and cellular
mechanisms through which RAGE mediates metastasis," said
Barry Hudson, PhD, associate
professor of oncology at Georgetown
University's Lombardi Comprehensive Cancer Center and senior
author of the study. "Importantly, given the favorable safety
profile that azeliragon has displayed in human studies, we believe
there is strong rationale for studying its potential in clinical
trials to treat or prevent metastatic triple-negative breast
cancer."
The authors of the peer-reviewed article were comprised of cell
and cancer biology researchers at the University of Miami, Miller
School of Medicine, and Georgetown University. Cantex
recently announced the expansion of collaboration with researchers
at Georgetown's Lombardi Comprehensive Cancer Center and the
licensing from Georgetown University of
intellectual property related to the potential use of azeliragon to
treat, prevent or alleviate cancer-treatment related cognitive
decline. Hudson and study co-author Marc
Lippman, at Georgetown
University, are named inventors on the patent application
related to the Georgetown license.
About Azeliragon
Azeliragon is an orally administered
capsule, taken once daily, that inhibits interactions of the
receptor for advanced glycation end products (known as RAGE) with
certain ligands, including HMGB1 and S100 proteins in the
tumor microenvironment. Azeliragon was originally under development
for Alzheimer's disease by vTv Therapeutics Inc.
(NASDAQ: VTVT) from which Cantex licensed worldwide rights to
azeliragon. Clinical safety data from these trials, involving more
than 2000 individuals dosed for periods up to 18 months, indicate
that azeliragon is very well tolerated. Cantex has ongoing
clinical trials in neoadjuvant therapy of breast cancer, metastatic
pancreatic cancer, and hospitalized COVID-19 patients to prevent
acute kidney injury and will soon initiate FDA-approved phase 2
clinical trials of azeliragon in newly diagnosed glioblastoma, and
in brain metastases in combination with stereotactic radiosurgery
as well as in combination with whole brain radiation therapy. These
trials are based on robust pre-clinical data as well as the
extensive clinical safety information from randomized
placebo-controlled clinical trials.
About Cantex Pharmaceuticals, Inc.
Cantex
Pharmaceuticals, Inc. is a privately held, clinical-stage
pharmaceutical company focused on developing transformative
therapies for cancer and other life-threatening medical conditions
for which new treatments are urgently needed. For more information,
please visit www.cantex.com.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a
clinical stage biopharmaceutical company focused on developing
oral, small molecule drug candidates, led by cadisegliatin (TTP399)
for the treatment of type 1 diabetes. To learn more please visit
vtvtherapeutics.com.
Contact Data:
Tiberend Strategic Advisors, Inc.
Investors
Daniel Kontoh-Boateng
+1 862-213-1398
dboateng@tiberend.com
Media
Casey McDonald
+1 646-577-8520
cmcdonald@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-announces-article-published-in-npj-breast-cancer-highlighting-potential-role-of-rage-inhibition-to-prevent-metastasis-in-triple-negative-breast-cancer-301897258.html
SOURCE Cantex Pharmaceuticals, Inc.
